Providing predictive drug discovery that involves merging human biology with computational biology to accelerate preclinical drug discovery, Javelin Biotech is developing a preclinical drug testing platform that integrates Organ-on-Chip (OoC) technologies and computational biology/artificial intelligence to optimize lead selection and clinical trial design for the pharmaceutical industry. DMPK, safety toxicology, and mechanism of action studies using human OoC hardware generate the most human-relevant, in vitro data. Javelin Bio translates these experimental results into predictions that impact IND submissions and guide clinical trial designs. Javelin Biotech management that their objective is to develop industry-leading organ-on-a-chip predictive pharmacokinetics platform in three-year collaboration with Pfizer Inc.
